Vanguard Group’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-446,972
| Closed | -$143K | – | 4145 |
|
|
2018
Q1 | $143K | Buy |
446,972
+137,083
| +44% | +$205K | ﹤0.01% | 3998 |
|
|
2017
Q4 | $512K | Sell |
309,889
-49,862
| -14% | -$85.8K | ﹤0.01% | 3743 |
|
|
2017
Q3 | $518K | Buy |
359,751
+18,750
| +5% | +$26.6K | ﹤0.01% | 3744 |
|
|
2017
Q2 | $553K | Buy |
341,001
+4,546
| +1% | +$10.2K | ﹤0.01% | 3706 |
|
|
2017
Q1 | $1.15M | Buy |
336,455
+110,864
| +49% | +$524K | ﹤0.01% | 3542 |
|
|
2016
Q4 | $1.17M | Buy |
225,591
+30,772
| +16% | +$533K | ﹤0.01% | 3513 |
|
|
2016
Q3 | $4.91M | Buy |
194,819
+9,468
| +5% | +$239K | ﹤0.01% | 3024 |
|
|
2016
Q2 | $4.58M | Buy |
185,351
+5,911
| +3% | +$167K | ﹤0.01% | 3032 |
|
|
2016
Q1 | $5.2M | Buy |
179,440
+12,850
| +8% | +$349K | ﹤0.01% | 2941 |
|
|
2015
Q4 | $6.18M | Buy |
166,590
+6,904
| +4% | +$305K | ﹤0.01% | 2892 |
|
|
2015
Q3 | $7.78M | Buy |
159,686
+19,691
| +14% | +$1.38M | ﹤0.01% | 2735 |
|
|
2015
Q2 | $9.65M | Buy |
139,995
+8,185
| +6% | +$379K | ﹤0.01% | 2687 |
|
|
2015
Q1 | $4.71M | Buy |
131,810
+62,998
| +92% | +$1.86M | ﹤0.01% | 3026 |
|
|
2014
Q4 | $869K | Buy |
68,812
+2,613
| +4% | +$38K | ﹤0.01% | 3572 |
|
|
2014
Q3 | $1.02M | Buy |
66,199
+7,331
| +12% | +$154K | ﹤0.01% | 3502 |
|
|
2014
Q2 | $1.6M | Buy |
58,868
+5,362
| +10% | +$132K | ﹤0.01% | 3348 |
|
|
2014
Q1 | $1.43M | Buy |
53,506
+11,532
| +27% | +$293K | ﹤0.01% | 3344 |
|
|
2013
Q4 | $1.03M | Sell |
41,974
-1,729
| -4% | -$44.6K | ﹤0.01% | 3406 |
|
|
2013
Q3 | $1.41M | Buy |
43,703
+100
| +0.2% | +$3.1K | ﹤0.01% | 3270 |
|
|
2013
Q2 | $1.29M | Buy |
+43,603
| New | +$1.63M | ﹤0.01% | 3230 |
|
Other funds holding ANTH
Vanguard Group's ANTH Position: Q2 2018 in Review
Vanguard Group sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 446,972 shares — an estimated $143K sold.
Vanguard Group first reported a position in ANTH in Q2 2013 and held it in 20 quarters. The position peaked at $9.65M in Q2 2015. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.
- Vanguard Group reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
- Vanguard Group sold 446,972 Anthera Pharmaceuticals, Inc. shares in Q2 2018, an estimated $143K.
- Vanguard Group first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 20 quarters.
- Vanguard Group's Anthera Pharmaceuticals, Inc. position peaked at $9.65M in Q2 2015.
- 5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.
Based on Vanguard Group's 13F filing for Q2 2018, filed 14 Aug 2018.